News


All series


All News

Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy. The approval is based on results from 53 patients with relapsed/refractory PMBCL enrolled in the multicenter, open-label, single-arm KEYNOTE‑170 trial.

A supplemental new drug application adding overall survival data from the phase III ASPIRE trial to the label for carfilzomib (Kyprolis) has been approved by the FDA, according to Amgen, the manufacturer of the proteasome inhibitor.  Carfilzomib is approved for use in patients with relapsed or refractory multiple myeloma.

During a presentation at the 2018 Community Oncology Conference, hosted by the Community Oncology Alliance, Bob Twillman, PhD, emphasized a lack of understanding within the medical community on pain management. He referenced a survey conducted by the Association of American Medical Colleges, which found that a significantly small percentage of medical schools included a separate course in pain management in their curriculum.

Although patients who develop brain metastases from renal cell carcinoma typically have poor outcomes, investigators from Yale University have identified a subset of patients who demonstrated extended survival.<sup>1</sup>Those patients with a single metastasis were less likely to develop central nervous system\ recurrence after local therapy. This is an encouraging development because these patients have historically been excluded from participating in clinical trials and receiving aggressive treatment regimens.

An objective response rate was achieved in 18 of 37 patients with&nbsp;relapsed/refractory non-Hodgkin lymphoma who received the combination of&nbsp;the BTK inhibitor ibrutinib with the PI3K inhibitor buparlisib, according to findings of a phase I/II trial&nbsp;reported at the 2018 ASCO Annual Meeting.

Progression-free survival was found to be almost identical at 48 weeks with&nbsp;MYL-1401O in combination with a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance versus trastuzumab in patients with HER2-positive metastatic breast cancer, according to phase III findings of the&nbsp;HERITAGE trial. Results of the trial were presented at the 2018 ASCO Annual Meeting.

The 2018 ASCO Annual Meeting was a great success, with over 40,000 people in attendance and over 5000 abstracts presented from June 1-5 in Chicago, Illinois. Data from several phase III trials in lung cancer were presented, with especially significant results in non&ndash;small cell lung cancer. Other big areas during this year&rsquo;s meeting included breast, gastrointestinal, genitourinary, and hematologic cancers.

In results from the phase III REACH-2 trial,&nbsp;ramucirumab reduced the risk of death by 29% versus placebo as a second-line treatment for&nbsp;patients with advanced hepatocellular carcinoma. Results from the study were presented during the&nbsp;2018 ASCO Annual Meeting.

The investigational second-generation tyrosine kinase inhibitor dacomitinib demonstrated an improved median overall survival of 34.1 months compared to 26.8 months with&nbsp;gefitinib as a first-line treatment for patients with advanced,&nbsp;<em>EGFR</em>-mutant non&ndash;small cell lung cancer, according to data from a open-label, phase III trial presented at the 2018 ASCO Annual Meeting.<sup>1</sup>

Based on data reported at the 2018 ASCO Annual Meeting, the primary endpoint of the phase III RELEVANCE trial was not met with the combination of rituximab plus lenalidomide showing similar efficacy results compared with rituximab plus chemotherapy in treatment-naive patients with follicular lymphoma. The chemotherapy-free regimen, however, did show a more favorable toxicity profile.&nbsp;

Treatment-naive patients with chronic lymphocytic leukemia achieved high rates of&nbsp;minimal residual disease&ndash;negative status of 77% with peripheral blood testing after 6 cycles from treatment with ibrutinib (Imbruvica) and venetoclax (Venclexta). Additionally, patients in the CAPTIVATE trial, wihch was presented during the 2018 ASCO Annual Meeting, achieved an objective response rate of 100%.

An FDA analysis of data from 2 randomized clinical trials investigating pembrolizumab in multiple myeloma showed inconsistent results regarding the relationship between immune-related adverse events and objective responses. The KEYNOTE-183 and KEYNOTE-185 trials were reviewed during the 2018 ASCO Annual Meeting.